Early safety study of LY4167586 in adults with obesity, overweight or type 2 diabetes
Tests how safe LY4167586 is in adults with obesity or overweight.
Plain-language title generated from the registry record
Registry title: A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
Key facts
- Where
- Anaheim, Columbus, Dallas, Daytona Beach, Decatur, Los Alamitos, Marlton, Miami, San Antonio, Walnut Creek, and Winter Park, United StatesSee the 11 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07881887, who can take part
Where in United States
- CenExel ACTAnaheim, United StatesNo longer taking part
- Ohio Clinical TrialsColumbus, United StatesNo longer taking part
- Fortrea Clinical Research UnitDallas, United StatesNo longer taking part
- Fortrea Clinical Research UnitDaytona Beach, United StatesNo longer taking part
- CenExel iResearch, LLCDecatur, United StatesNo longer taking part
- Collaborative Neuroscience Network - CNSLos Alamitos, United StatesNo longer taking part
- CenExel-HRIMarlton, United StatesNo longer taking part
- Advanced Pharma CR, LLCMiami, United StatesNo longer taking part
- Worldwide Clinical Trials, Inc.San Antonio, United StatesNo longer taking part
- Diablo Clinical Research, Inc.Walnut Creek, United StatesNo longer taking part
- Clinical Site Partners, LLC DBA CSP OrlandoWinter Park, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07881887
- Record updated
- 20 October 2026
- Original description
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.Read full original descriptionShow less
A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Dose Regimens of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.
Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
Inclusion: Participants must be 21 in Singapore; Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent (%) body weight change; Part A, B, D, and E; Have a body mass index (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:; hypertension; dyslipidemia; obstructive sleep apnea, or; prediabetes; Part C; Have a BMI ≥25.0 kg/m²; Have a diagnosis of Type 2 Diabetes (T2D) for at least 6 months; T2D controlled with diet and exercise alone or are on a stable dose of metformin alone, or in combination with a sodium-glucose co-transporter-2 inhibitor (SGLT-2i), for at least 3 months; Have a hemoglobin (HbA1c) value of ≥6.5 % and ≤10.0%; Part D; To qualify as Chinese for this study, the participant must be at a minimum third-generation Chinese, defined as having all 4 of the participants' biological grandparents being of exclusive Chinese descent and born in China; Part E; To qualify as Japanese for this study, the participant must be at a minimum third-generation Japanese, defined as having all 4 of the participants' biological grandparents being of exclusive Japanese descent and born in Japan.
Exclusion: Have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine (except for T2D in Part C), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.